T2 Biosystems, a medical diagnostic company based in Lexington, Massachusetts, has officially terminated its Equity Distribution Agreement with Canaccord Genuity LLC as of July 19, 2024. The agreement, which was initially entered into on March 31, 2021, allowed for the sale of T2 Biosystems' common stock through an 'at the market' equity offering program where Canaccord served as the sales agent. The termination of the agreement carries no penalties for T2 Biosystems. Details of the original Equity Distribution Agreement can be found in the company's Registration Statement on Form S-3 filed with the SEC on the same date the agreement was signed.

T2 Biosystems, a medical diagnostic company based in Lexington, Massachusetts, has officially terminated its Equity Distribution Agreement with Canaccord Genuity LLC as of July 19, 2024. The agreement, which was initially entered into on March 31, 2021, allowed for the sale of T2 Biosystems' common stock through an 'at the market' equity offering program where Canaccord served as the sales agent. The termination of the agreement carries no penalties for T2 Biosystems. Details of the original Equity Distribution Agreement can be found in the company's Registration Statement on Form S-3 filed with the SEC on the same date the agreement was signed.